Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices - Scorecard - MDSpire

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

  • By

  • Himani Aggarwal

  • Ke Zu

  • Carole R. Berini

  • Paul Conkling

  • Carlos Yugar

  • Jinhong Guo

  • Jerome Goldschmidt

  • May 22, 2026

  • 0 min

Share

Clinical Scorecard: Treatment Approaches and Outcomes for Patients with Extensive-Stage Small-Cell Lung Cancer in Community Oncology Settings in the United States

At a Glance

CategoryDetail
Condition
Key MechanismsIntegration of immune checkpoint inhibitors (ICIs) with platinum-based chemotherapy and consideration of T-cell engagers.
Target Population
Care Setting

Key Highlights

  • median_overall_survival

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • f
      • o
      • l
      • l
      • o
      • w
      • -
      • u
      • p
      • f
      • r
      • e
      • q
      • u
      • e
      • n
      • c
      • y
      • a
      • n
      • d
      • t
      • y
      • p
      • e
      • s
      • o
      • f
      • a
      • s
      • s
      • e
      • s
      • s
      • m
      • e
      • n
      • t
      • s
      • .

      Risks

        Patient & Prescribing Data

        Adult patients aged ≥ 18 years with ES-SCLC

        Majority received ICI plus chemotherapy as first-line treatment

        Clinical Best Practices

        • additions

        Related Resources & Content

        Original Source(s)

        Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

        • by Himani Aggarwal, Ke Zu, Carole R. Berini, Paul Conkling, Carlos Yugar, Jinhong Guo, Jerome Goldschmidt

        • May 22, 2026

        Related Content

        The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

        Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

        Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen